CLX

Business profile & competitive position

The Clorox Company operates in the Consumer Defensive sector, specifically the Household & Personal Products industry. It is a multinational manufacturer and marketer of consumer and professional products, with fiscal 2026 net sales of $6.7 billion and approximately 9,200 employees operating in about 25 countries and selling in roughly 95 markets. Its consumer-facing brand portfolio includes Clorox, Pine-Sol, Glad, Fresh Step, Kingsford, Hidden Valley, Brita, and Burt’s Bees, while its professional division sells Purell, CloroxPro, and Clorox Healthcare products.

On the surface, the roster of market-leading household names suggests a stable, brand-driven business. The numbers, however, tell a more complicated story. The company’s net margin of 8.7% shows it still converts sales into profit, but the reported return on equity of -1893.5% is an extreme negative reading that implies shareholders’ equity has been deeply eroded—likely through accumulated losses, heavy buybacks, or liability restructuring—rather than expanded. A business with familiar shelf placement does not automatically translate into healthy book-value economics, and the divergence between a positive P/E and a massively negative ROE is the central tension in Clorox’s current competitive profile. Its beta of 0.54 means the stock has moved less than half as much as the broader market, consistent with a defensive consumer name, yet that low volatility has not shielded equity value from fundamental deterioration.

Customer concentration adds pressure. Walmart alone accounted for 26% of consolidated fiscal 2026 net sales, and the five largest customers represented about half. That dependence limits pricing power and raises execution risk if any large retailer changes shelf space, terms, or inventory levels.

Financial posture

Clorox currently carries a market capitalization of $9.9 billion and trades at a P/E ratio of 17.0, using the latest available snapshot price of $82.01. A P/E near 17 is not unusual for a consumer defensive name, but it sits against the backdrop of a -1893.5% ROE, an almost impossible-looking figure that signals the company’s equity base is either negative or insignificantly small relative to its earnings. In other words, the market is valuing earnings power rather than a robust balance sheet.

The net margin of 8.7% supports the idea that operations still produce profits, yet margin compression, restructuring costs, or balance-sheet leverage appear to have overwhelmed the equity account. The beta of 0.54 confirms low market sensitivity, which is typical for staples but also means the stock can underperform in risk-on rallies even when fundamentals stabilize. At present, the 50-day EMA stands at $91.27, while the price is $82.01—roughly 10% below that short-term trend, and the RSI of 35.2 places the stock near the lower bound of neutral territory. None of these figures alone indicates direction, but together they describe a defensive stock under distribution pressure rather than one riding a stable uptrend.

Strategic priorities & outlook

Management’s stated priorities, as drawn from the company’s most recent SEC 10-K filing, revolve around the IGNITE strategy. That strategy is built on four choices: fueling long-term profitable growth, innovating consumer experiences, reimagining how the company and its people work, and continuously evolving the product portfolio.

Operationally, Clorox is focused on completing and optimizing a new enterprise resource planning (ERP) system and broader digital transformation to generate long-term efficiencies across supply chain, digital commerce, innovation, and brand building. It also intends to invest in strong brands, strategic digital capabilities, and a streamlined operating model to build what it calls a more resilient company capable of delivering consistent, profitable growth. A third pillar is advancing health and hygiene expansion and portfolio optimization, including integrating the GOJO Industries acquisition completed in April 2026 and growing professional and institutional markets.

The filing also flags headwinds. Fiscal year 2026 saw declines in organic sales and earnings, with diluted EPS down 26%, partly due to macroeconomic pressures and ERP transition timing that had pulled some sales forward into fiscal 2025. Additionally, the Glad bags and wraps venture with Procter & Gamble expired on January 31, 2026, requiring Clorox to purchase P&G’s 20% interest; Glad retained core intellectual property licenses on a royalty-free basis. These items suggest the outlook is more about stabilizing operations and digesting change than about returning to high-single-digit top-line growth in the immediate term.

Macro & geopolitical exposure

As a Household & Personal Products company, Clorox faces macro exposures common to the staples industry. Input costs are the most visible: plastics, resins, paper, chemicals, energy, and freight all feed into packaging and manufacturing. When commodity or energy prices rise, margins compress unless pricing power is strong enough to pass costs through; with Walmart representing 26% of sales, that pass-through power is not unlimited.

Currency risk is also relevant. The company operates in approximately 25 countries and sells in about 95 markets, so a stronger U.S. dollar reduces the value of overseas revenue and earnings when translated back. Trade policy, including tariffs on imported raw materials or finished goods, can affect both cost structures and supply chain routing. Regulatory exposure is built into the industry as well, from EPA registration of disinfectants to labeling and consumer-product safety rules.

Demand for cleaning, charcoal, salad dressing, and trash bags is relatively recession-resistant, which explains the 0.54 beta and defensive classification. Still, that resilience is mostly a demand-side cushion; it does not eliminate margin or balance-sheet risk.

Recent developments

Clorox has drawn significant analyst and media attention in early October 2026. On October 5, Benzinga published “Wall Street’s Most Accurate Analysts Spotlight On 3 Defensive Stocks Delivering High-Dividend Yields,” placing Clorox in a defensive-income discussion. On October 3, The Motley Fool ran two pieces: one comparing Clorox, General Mills, and Constellation Brands—noting all three had fallen 22% to 33%—and another titled “Clorox is Dealing With Several Years of Challenging Circumstances.” The latter headline mirrors the 10-K description of multi-year pressure and the 26% diluted EPS drop in fiscal 2026. On October 2, Defense World reported that Clorox reached a new 52-week low, citing “Clorox (NYSE:CLX) Reaches New 52-Week Low – Here’s Why.” The clustering of these headlines around the same week reflects broad recognition that the stock has weakened even as the business remains a familiar household name.

Earnings behavior & post-earnings drift

Over the last eight reported quarters, Clorox has beaten earnings estimates six times, a 75% beat rate, with an average earnings surprise of 9.6%. The average five-day price move following those reports is 1.67% to the upside, classified as an upward post-earnings drift. That said, the most recent quarters show significant noise beneath the headline averages.

For the August 3, 2026 report, Clorox delivered $1.66 versus a $1.64 estimate, a 1.2% surprise, and the stock rose 6.52% the next day and 9.61% over the following five sessions. The April 30, 2026 quarter was a beat on the surface—$1.64 actual versus $1.55 estimate, a 5.8% surprise—but the market sold it off sharply, with the stock dropping 9.67% the next day and 4.49% over five days. That divergence between a positive surprise and negative price reaction can happen when outlook commentary or margin guidance disappoints.

The February 3, 2026 report was a miss, with $1.39 versus $1.43 estimate, yet the stock moved up 2.43% the next day and 5.63% over five days. Finally, the November 3, 2025 quarter showed a beat, $0.85 versus $0.818 estimate, but the stock drifted lower, slipping 4.08% over five days. The next scheduled report is November 3, 2026 after the close, with a consensus EPS estimate of $1.09. The unofficial consensus, combined with the 75% beat rate and the 1.67% average upward drift, gives traders a quantitative framework, but the wide divergence between surprise direction and price direction in recent reports shows that the reaction mechanism is not purely about whether Clorox beats the headline number.

For a deeper look at how institutional analysts are interpreting these crosscurrents—and whether the November 3 report is expected to confirm stabilization or extend the earnings decline—review the full institutional verdict on CLX.